Evidence map›Paper›PMID 38405668›Full record

ArticleFrontiers in pharmacology2024

Editorial: Repurposing β-blockers for non-cardiovascular diseases.

Ayaz Shahid, Jeffrey Wang, Bradley T Andresen, S R Wayne Chen, Ying Huang

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ayaz ShahidDepartment of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, United States.
Jeffrey WangDepartment of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, United States.
Bradley T AndresenDepartment of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, United States.
S R Wayne ChenDepartment of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada.
Ying HuangDepartment of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, United States.

Funding

Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilolR01CA269653 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI Ying Huang · 2022 to 2026
$1.6M
Chemoprevention of lung cancer with the β-blocker carvedilolR03CA256241 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI HUANG, YING · 2021 to 2022
$141k
NCI NIH HHS R01 CA269653NCI NIH HHS R03 CA256241
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

B-blockerscancernon-cardiovascular diseasessepsisβ-adrenergic receptor

Identifiers

PMID38405668
PMCPMC10884952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.